CR20150077A - Composición farmacéutica oral en forma de microesferas y proceso de elaboración - Google Patents
Composición farmacéutica oral en forma de microesferas y proceso de elaboraciónInfo
- Publication number
- CR20150077A CR20150077A CR20150077A CR20150077A CR20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A CR 20150077 A CR20150077 A CR 20150077A
- Authority
- CR
- Costa Rica
- Prior art keywords
- microspheres
- pharmaceutical composition
- oral pharmaceutical
- elaboration process
- elaboration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición en forma de micropartículas que constanprincipalmente de: a) un núcleo inerte; b) una capa deprincipio activo formada por aspersión sobre el núcleoinerte y c) opcionalmente un segundo recubrimiento quecomprende una o más capas de fármaco(s) y/o excipiente(s)farmacéuticamente aceptable(s).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012009583A MX351059B (es) | 2012-08-17 | 2012-08-17 | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. |
PCT/IB2013/056690 WO2014027334A2 (es) | 2012-08-17 | 2013-08-16 | Composicion farmacéutica oral en forma de microesferas y proceso de elaboración |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150077A true CR20150077A (es) | 2015-05-13 |
Family
ID=50435594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150077A CR20150077A (es) | 2012-08-17 | 2015-02-13 | Composición farmacéutica oral en forma de microesferas y proceso de elaboración |
Country Status (8)
Country | Link |
---|---|
CL (1) | CL2015000375A1 (es) |
CO (1) | CO7310526A2 (es) |
CR (1) | CR20150077A (es) |
DO (1) | DOP2015000028A (es) |
GT (1) | GT201500035A (es) |
MX (1) | MX351059B (es) |
PE (1) | PE20150710A1 (es) |
WO (1) | WO2014027334A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2978859B1 (en) | 2013-03-27 | 2018-06-27 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
CN104523710B (zh) * | 2014-12-30 | 2018-05-25 | 石药集团欧意药业有限公司 | 一种硫酸氢氯吡格雷阿司匹林复合双层片及其制备方法 |
KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
EP3582777A4 (en) | 2017-02-17 | 2020-12-23 | Unichem Laboratories Ltd | PHARMACEUTICAL COMPOSITION OF APIXABAN |
CN106821996A (zh) * | 2017-03-01 | 2017-06-13 | 华益药业科技(安徽)有限公司 | 马来酸依那普利颗粒剂及其制备方法 |
BR112020020941A2 (pt) * | 2018-04-16 | 2021-03-02 | Bristol-Myers Squibb Company | formulações apixaban |
WO2021168043A1 (en) * | 2020-02-19 | 2021-08-26 | Nano Pharmasolutions, Inc. | Therapeutic agent nanoparticles and methods of preparation |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
CN113413364A (zh) * | 2021-05-31 | 2021-09-21 | 辰欣药业股份有限公司 | 一种依诺肝素钠注射液及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007208998A1 (en) * | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
MXPA06010972A (es) * | 2006-09-25 | 2009-04-17 | World Trade Imp Export Wtie Ag | Proceso para estabilizacion de famotidina. |
WO2008045006A1 (en) * | 2006-10-11 | 2008-04-17 | Fako Ilaclari A. S. | Formulations of candesartan |
MX2007008440A (es) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Composicion farmaceutica combinada. |
-
2012
- 2012-08-17 MX MX2012009583A patent/MX351059B/es active IP Right Grant
-
2013
- 2013-08-16 WO PCT/IB2013/056690 patent/WO2014027334A2/es active Application Filing
- 2013-08-16 PE PE2015000210A patent/PE20150710A1/es active IP Right Grant
-
2015
- 2015-02-13 CR CR20150077A patent/CR20150077A/es unknown
- 2015-02-16 GT GT201500035A patent/GT201500035A/es unknown
- 2015-02-16 DO DO2015000028A patent/DOP2015000028A/es unknown
- 2015-02-17 CL CL2015000375A patent/CL2015000375A1/es unknown
- 2015-03-04 CO CO15048826A patent/CO7310526A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
GT201500035A (es) | 2017-10-24 |
WO2014027334A3 (es) | 2014-04-10 |
DOP2015000028A (es) | 2015-03-15 |
PE20150710A1 (es) | 2015-05-28 |
MX351059B (es) | 2017-09-29 |
WO2014027334A2 (es) | 2014-02-20 |
MX2012009583A (es) | 2014-02-26 |
CL2015000375A1 (es) | 2015-07-10 |
CO7310526A2 (es) | 2015-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150077A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
CY1120783T1 (el) | Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας | |
CL2013000424A1 (es) | Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c). | |
CL2014002754A1 (es) | Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014). | |
CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
FI20145771L (fi) | Parasitisidaalisia oraalisia eläinlääkekoostumuksia, jotka käsittävät systeemisesti vaikuttavan aktiiviaineen, menetelmiä ja käyttöjä | |
AR096439A1 (es) | Forma de dosificación resistente al uso indebido que contiene una o más partículas | |
CL2014000904A1 (es) | Forma de dosis farmaceutica oral resistente a la ruptura que comprende i) un ingrediente farmacologicamente activo, ii) un antagonista opioide y/o un agente repelente, iii) un oxido de polialquileno y iv) un polimero anionico. | |
CR20140487A (es) | Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo | |
BR112014012005A2 (pt) | composições, métodos, formulação farmacêutica e artigo | |
CL2014001016A1 (es) | Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. | |
CL2013003650A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable. | |
CR20160067A (es) | Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel | |
BR112013030472A2 (pt) | formulação farmacêutica, artigo de fabricação e método | |
SMT201500126B (it) | Nuova composizione farmaceutica resistente all'abuso per il trattamento di una dipendenza da oppioidi | |
WO2011140446A3 (en) | Pharmaceutical formulations | |
CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
EP3481381A4 (en) | ORAL PHARMACEUTICAL FORM WITH ACTIVE COMPOSITION, BARRIER AND ACTIVE LAYER | |
CL2014002988A1 (es) | Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo. | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
GT201400042A (es) | Compuesto de benzotiazolona |